9360 Towne Centre Drive
Tel: 1 858 926 2900
31 articles with Biosplice Therapeutics
Biosplice Therapeutics, Inc. announced today the addition of Dave Johnson, most recently Founder and CEO of VelosBio, as an independent director to its board.
5/3/2021Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications.
Samumed, LLC, a clinical-stage biotechnology company pioneering Wnt Pathway therapeutics for major diseases, announced that Dr. Michael White will join the company as its Chief Scientific Officer.
5/26/2020Non-COVID-19 clinical trial updates are outweighing COVID-19 studies, particularly with the American Society of Clinical Oncology meeting coming up soon. Here’s a look.
Samumed Announces Publication of Phase 2 Data on Lorecivivint, Now in Pivotal Trials for Knee Osteoarthritis
X-ray results and pain and function responses highlight the potential of lorecivivint as a first-in-class drug for the treatment of knee osteoarthritis
1/21/2020The Wnt pathway is a mastermind signaling pathway in your cells, creating a complex dance of proteins that must be choreographed and executed correctly for proper cell functioning.
11/18/2019It was a busy week for clinical trial announcements. Here’s a look.
Samumed Presents Safety Data Analysis of Lorecivivint for Knee Osteoarthritis at the 2019 ACR Annual Meeting
Samumed, LLC, presented a new clinical safety analysis of lorecivivint, a CLK/DYRK1A inhibitor that modulates the Wnt pathway, in a poster presentation at the 2019 American College of Rheumatology (ACR) Annual Meeting.
Samumed And United Therapeutics Announce North American License Agreement For Samumed's IPF Drug Candidate
Samumed LLC has entered an exclusive license agreement with United Therapeutics Corporation (Nasdaq: UTHR) for North American rights to Samumed's SM04646, being developed for the treatment of idiopathic pulmonary fibrosis (IPF).
Samumed, LLC, announced today that it has closed its A-6 Round of equity issuance with $438 million, bringing its total equity raised to date to more than $650 million. The pre-money valuation for the round was $12 billion.
Samumed, today announced the dosing of the first degenerative disc disease patient in its Phase 1 trial of SM04690, a small molecule Wnt pathway inhibitor formulated as an intradiscal injection.
This Phase 1, open-label, multi-center, dose-escalation study will evaluate the safety, tolerability and pharmacokinetics (PK) of orally administered SM08502 in subjects with advanced solid tumors.
Samumed Announces Results of Phase II Trial of SM04690 Demonstrating Evidence of Cartilage Regeneration in Patients With Knee Osteoarthritis
Data support potential of SM04690 as a disease modifying drug for knee osteoarthritis.
Top-line data is expected by Q2 2018.
Samumed Announces 52-week Phase II Osteoarthritis Data Supporting the Potential of SM04690 as a Disease Modifying Drug
Samumed will be presenting data in three presentations at the 2017 ACR/ARHP Annual Meeting.
Samumed Successfully Completes Phase I Study For Potential Topical Treatment For Chronic Tendinopathy
Samumed Successfully Completed Phase I Study For Potential Treatment Of Idiopathic Pulmonary Fibrosis